YM155 enhances docetaxel efficacy in ovarian cancer.

about

YM155 enhances docetaxel efficacy in ovarian cancer.

Item

http://www.wikidata.org/entity/Q52595117

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

YM155 enhances docetaxel efficacy in ovarian cancer.

@en

YM155 enhances docetaxel efficacy in ovarian cancer.

@nl

type

Item

label

YM155 enhances docetaxel efficacy in ovarian cancer.

@en

YM155 enhances docetaxel efficacy in ovarian cancer.

@nl

prefLabel

YM155 enhances docetaxel efficacy in ovarian cancer.

@en

YM155 enhances docetaxel efficacy in ovarian cancer.

@nl

P1476

YM155 enhances docetaxel efficacy in ovarian cancer.

@en

P2093

Jia-Rong Huang

http://www.w3.org/2001/XMLSchema#string

Kun Wang

http://www.w3.org/2001/XMLSchema#string

Li-Jiao Hou

http://www.w3.org/2001/XMLSchema#string

Li-Na Xu

http://www.w3.org/2001/XMLSchema#string

Meng-Ling Yuan

http://www.w3.org/2001/XMLSchema#string

Meng-Ning Wei

http://www.w3.org/2001/XMLSchema#string

Na Zhao

http://www.w3.org/2001/XMLSchema#string

Qi-Wei Jiang

http://www.w3.org/2001/XMLSchema#string

Rong-Ying Ou

http://www.w3.org/2001/XMLSchema#string

Wen-Feng Li

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel

Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.

Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells.

Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3.

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

Cables1 complex couples survival signaling to the cell death machinery

Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.

P304

696-708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29636860

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5883111

http://www.w3.org/2001/XMLSchema#string